E.E. Voest
The Netherlands Cancer Institute · UMC Utrecht
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name E.E. Voest as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02925234 · The Drug Rediscovery Protocol (DRUP Trial)The Netherlands Cancer Institute · recruiting · Cancer, Tumors, Neoplasm · principal investigator
- Ph2NCT01408004 · Rotating Pazopanib and Everolimus to Avoid ResistanceNetherlands Working Group on Immunotherapy of Oncology · completed · Clear Cell Renal Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:50 UTC. The ranking covers the 200 most relevant of 70 PubMed records, and a shared surname and initials can bring in a namesake. All 70 on PubMed
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.Nat Med · 20201,181 citationsRCR 45.7
- Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.N Engl J Med · 20091,070 citationsRCR 24.2
- Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.N Engl J Med · 2024404 citationsRCR 44.1
- The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.Nature · 2019214 citationsRCR 6.1
- High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.N Engl J Med · 2003195 citationsRCR 4.1
- A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.Clin Cancer Res · 2007142 citationsRCR 3.8
- A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma.J Clin Endocrinol Metab · 2007132 citationsRCR 3.3
- Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.Nat Med · 2024131 citationsRCR 14.1
- 129 citationsRCR 5.2
- Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.J Clin Oncol · 200698 citationsRCR 2.2